Claims for Patent: 9,222,081

Summary for Patent: 9,222,081

Title:	Method of producing and purifying an active soluble sialyltransferase
Abstract:	The present invention relates to a method for the production and purification of a sialyltransferase polypeptide, in particular a N-Acetylgalactosamine (Gal NAc)-.alpha.-2,6-sialyltransferase I (ST6GalNAcI) polypeptide. The method comprises the steps of producing the sialyltransferase polypeptide in a Chinese Hamster Ovary (CHO) cell and purifying the polypeptide with a combination of chromatography steps. The method results in high yield of sialyltransferase polypeptide which is highly pure and active. The obtained sialyltransferase, especially ST6GalNAcI, can be employed for the glycosylation of therapeutic proteins such as G-CSF.
Inventor(s):	Angermann; Axel (Dreieich, DE), Scheckermann; Christian (Ehrenkirchen, DE), Schmidt; Karsten (Karlsruhe, DE)
Assignee:	BIOGENERIX GMBH (Ulm, DE)
Application Number:	13/813,804
Patent Claims:	1. A method of producing a sialyltransferase polypeptide, which comprises the steps of: a) expressing a sialyltransferase polypeptide in Chinese hamster ovary cells; collecting the cell culture medium containing the expressed sialyltransferase polypeptide, wherein an expression cassette encoding an erythropoietin (EPO) signal sequence and a sialyltransferase polypeptide sequence is used for expressing the sialyltransferase polypeptide in Chinese hamster ovary cells; b) purifying the sialyltransferase polypeptide from the cell culture medium by subjecting the cell culture medium to (i) two affinity chromatography steps or one affinity chromatography step and one mixed-mode chromatography step, (ii) one anion exchange chromatography step and (iii) one cation exchange chromatography step; and c) obtaining an eluate comprising the purified sialyltransferase polypeptide. 2. The method according to claim 1, wherein the sialyltransferase is ST6GalNAcI. 3. The method according to claim 2, wherein the ST6GalNAcI is selected from the group consisting of: human, chimpanzee, orangutan, pig, cow, dog, rat, mouse and chicken ST6GalNAcI. 4. The method according to claim 2, wherein the ST6GalNAcI is a chicken ST6GalNAcI. 5. The method according to claim 2, wherein the ST6GalNAcI polypeptide comprises an amino acid sequence according to SEQ ID NO: 4 or SEQ ID NO: 6. 6. The method according to claim 1, wherein the sialyltransferase polypeptide consists of the sialyltransferase active domain. 7. The method according to claim 1, wherein the EPO signal sequence consists of the human erythropoietin exon 1, intron 1 and a portion of exon 2, wherein the portion of exon 2 codes for 27 amino acids comprising the following sequence: MGVHECPAWLWLLLSLLSLPLGLPVLG. 8. The method according to claim 1, wherein step a) is performed by applying an incubation temperature shift from 37.degree. C.+/-1.degree. C. to 32.degree. C.+/-1.degree. C. after reaching a cell density of equal or more than 5.times.10.sup.5 viable cells/ml. 9. The method according to claim 1, wherein step b) is performed in the following order: i. an anion exchange chromatography; ii. a first affinity chromatography; iii. a second affinity chromatography or a mixed-mode chromatography; iv. a cation exchange chromatography. 10. The method according to claim 1, wherein the anion exchange chromatography is performed using a resin carrying a quaternary ammonium as a functional group. 11. The method according to claim 10, wherein the anion exchange chromatography is performed using a NaCl/Tris-HCl buffer as eluent at a pH in the range between 7.0 and 8.0. 12. The method according to claim 1, wherein the first affinity chromatography is performed using a dye affinity chromatography. 13. The method according to claim 12, wherein the first affinity chromatography is performed using a Blue Sepharose Fast Flow resin. 14. The method according to claim 13, wherein the Blue Sepharose affinity chromatography is performed using a L-arginine hydrochloride/potassium phosphate buffer as eluent at a pH in the range between 7.0 and 8.0. 15. The method according to claim 1, wherein the mixed-mode chromatography is performed using a hydroxyapatite resin. 16. The method according to claim 15, wherein the hydroxyapatite affinity chromatography is performed using a NaCl/potassium phosphate buffer as eluent at a pH in the range between 6.3 and 7.3. 17. The method according to claim 1, wherein the cation exchange chromatography is performed with a resin that contains sulfopropyl cation exchange material. 18. The method according to claim 17, wherein the cation exchange chromatography is performed using SP-Sepharose High Performance resin. 19. The method according to claim 18, wherein the cation exchange chromatography is performed using a NaCl/potassium phosphate buffer as eluent at a pH in the range between 6.0 and 7.0. 20. The method according to claim 1, wherein step b) is performed in the following order: i. an anion exchange chromatography using a Q-Sepharose Fast Flow resin; ii. an affinity chromatography using a Blue Sepharose Fast Flow resin; iii. a mixed-mode chromatography using a hydroxyapatite resin; iv. a cation exchange chromatography using a SP-Sepharose High Performance resin.

Details for Patent 9,222,081

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2030-08-02
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2030-08-02
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2030-08-02